Akebia Therapeutics, Inc. (AKBA)
0.7922
-0.01
(-1.11%)
USD |
NASDAQ |
Oct 12, 16:00
0.7922
0.00 (0.00%)
After-Hours: 17:15
Akebia Therapeutics Free Cash Flow (Quarterly) : 2.446M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.446M |
| March 31, 2026 | -21.27M |
| December 31, 2025 | 31.06M |
| September 30, 2025 | 28.03M |
| June 30, 2025 | 22.22M |
| March 31, 2025 | -13.60M |
| December 31, 2024 | -4.468M |
| September 30, 2024 | -6.697M |
| June 30, 2024 | -10.10M |
| March 31, 2024 | -19.43M |
| December 31, 2023 | -2.308M |
| September 30, 2023 | -7.167M |
| June 30, 2023 | 3.629M |
| March 31, 2023 | -17.54M |
| December 31, 2022 | -54.68M |
| September 30, 2022 | 33.80M |
| June 30, 2022 | -30.66M |
| March 31, 2022 | -21.73M |
| December 31, 2021 | -62.81M |
| September 30, 2021 | -56.27M |
| June 30, 2021 | -63.14M |
| March 31, 2021 | -70.80M |
| December 31, 2020 | -31.10M |
| September 30, 2020 | -27.19M |
| June 30, 2020 | 37.18M |
| Date | Value |
|---|---|
| March 31, 2020 | -89.59M |
| December 31, 2019 | -92.36M |
| September 30, 2019 | 8.46M |
| June 30, 2019 | -40.34M |
| March 31, 2019 | -139.86M |
| December 31, 2018 | -74.53M |
| September 30, 2018 | -12.77M |
| June 30, 2018 | 8.823M |
| March 31, 2018 | -20.63M |
| December 31, 2017 | -16.83M |
| September 30, 2017 | -55.21M |
| June 30, 2017 | 24.22M |
| March 31, 2017 | -9.955M |
| December 31, 2016 | 95.62M |
| September 30, 2016 | -29.50M |
| June 30, 2016 | -28.20M |
| March 31, 2016 | 17.32M |
| December 31, 2015 | -22.98M |
| September 30, 2015 | -9.146M |
| June 30, 2015 | -12.14M |
| March 31, 2015 | -8.547M |
| December 31, 2014 | -9.224M |
| September 30, 2014 | -5.640M |
| June 30, 2014 | -6.698M |
| March 31, 2014 | -6.150M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Emergent BioSolutions, Inc. | 54.00M |
| Exelixis, Inc. | 300.92M |
| ADMA Biologics, Inc. | 27.28M |
| Arcutis Biotherapeutics, Inc. | 12.48M |
| Relay Therapeutics, Inc. | -54.11M |